The trajectory of Sildenafil presents a complex case for investors in the drug sector. While initially a phenomenal success, creating vast sums, the patent lapse and the subsequent flood of off-brand versions have considerably impacted revenue. This raises questions about the future viability of related medication projects and suggests that simply